Cover Image
Market Research Report

US Biodefense Market Outlook 2022

Published by RNCOS E-Services Pvt. Ltd. Product code 397989
Published Content info 45 Pages
Delivery time: 1-2 business days
Back to Top
US Biodefense Market Outlook 2022
Published: November 10, 2016 Content info: 45 Pages

The dangers posed by the weapons of mass destruction have caught the attention of every nation worldwide. These weapons can be characterized by their potential for large-scale destruction and the indiscriminate nature of their effects, notably against civilians. Increasing threat of biological, chemical as well as nuclear terrorism and disease outbreaks; along with growing R&D investments in the field of biotechnology is expected to drive biodefense market growth with a CAGR of 9% during the forecasted period of 2017-2022.

The report "US Biodefense Market Outlook 2022" unfolds the market scenario of the US BioDefense market. The report provides an overview of the Biodefense market with respect to biological defense. It further gives a detailed analysis of its sub-segment, with an in-depth study of the Biodefense market scenario prevalent in the country.

A detailed analysis was carried out in the research to understand the significance of the biodefense market in United States, which revealed that Anthrax is the biggest bioterrorism threat to the country, as it is highly infectious and communicable. The other major threats are Small Pox and Botulism. Further, a meticulous category-wise segmentation has provided the understanding of the biodefense-related demand parameters prevailing in the country.

The latter half of the report provides the status of the current rules and regulations that govern the Biodefense market. It also focuses on the analysis of current drivers, and the challenges of the market. The report further highlights the competitive landscape of the US BioDefense market, describing the business of the major industry players. On the whole, the report provides all the pre-requisite information for clients looking to make a debut in this industry, and facilitates them to formulate schemes while going for an investment/partnership in the US BioDefense industry.

Table of Contents

Table of Contents

1. Analyst View

2. Research Methodology

3. BioDefense - An Introduction

4. Global BioDefense Industry

5. BioDefense Industry Market Outlook to 2022

  • 5.1 Anthrax
  • 5.2 Small Pox
  • 5.3 Botulism
  • 5.4 Radiation

6. Industry Drivers

  • 6.1 Innovative Technology Advancing the BioDefense Industry
  • 6.2 Government Initiatives Contributing to BioDefense Infrastructure
  • 6.3 Research and Development Enhancing Drug Efficiency

7. Industry Roadblocks

  • 7.1 Biological threat detection: A National Challenge
  • 7.2 Stringent Norms: Barriers to Clinical Testing

8. Regulatory Framework

9. Competitive Landscape

  • 9.1 PharmAthene, Inc.
    • 9.1.1 Business Description
    • 9.1.2 Financial Overview
  • 9.2 Emergent BioSolutions
    • 9.2.1 Business Description
    • 9.2.2 Financial Overview
    • 9.2.3 Recent Developments
  • 9.3 Dynavax Technologies Corporation
    • 9.3.1 Business Description
    • 9.3.2 Financial Overview
  • 9.4 SIGA Technologies, Inc.
    • 9.4.1 Business Description
    • 9.4.2 Financial Overview
    • 9.4.3 Recent Developments
  • 9.5 Alnylam Pharmaceuticals, Inc.
    • 9.5.1 Business Description
    • 9.5.2 Financial Overview
    • 9.5.3 Recent Developments
  • 9.6 Cleveland Biolabs, Inc.
    • 9.6.1 Business Description
    • 9.6.2 Financial Overview

List of Figures:

  • Figure 4-1: Share of US BioDefense Market, 2016
  • Figure 5-1: BioDefense Market (Billion US$), 2015-2022
  • Figure 5-2: BioDefense Market by Product (%), 2016
  • Figure 5-3: Anthrax BioDefense Market (Billion US$), 2015-2022
  • Figure 5-4: Small Pox BioDefense Market (Billion US$), 2015-2022
  • Figure 5-5: Botulism BioDefense Market (Billion US$), 2015-2022
  • Figure 5-6: Radiation/Nuclear BioDefense Market (Billion US$), 2015-2022

List of Tables:

  • Table 3-1: Biological Weapons by Type
  • Table 6-1: Product Pipeline by Phase, 2016
  • Table 9-1: PharmAthene, Inc. - Key Financials (Million US$), 2013-2015
  • Table 9-2: Emergent Biosolutions - Key Financials (Million US$), 2013-2015
  • Table 9-3: Dynavax Technologies - Key Financials (Million US$), 2013-2015
  • Table 9-4: Siga Technologies - Key Financials (Million US$), 2013-2015
  • Table 9-5: Alnylam Pharmaceuticals, Inc. - Key Financials (Million US$), 2013-2015
  • Table 9-6: Cleveland Biolabs, Inc. - Key Financials (Million US$), 2013-2015
Back to Top